Pyrimidinone compounds, pharmaceutical compositions containing the compounds and the process for preparing the same

A pyrimidinone compound of formula (I) or pharmaceutically acceptable salts thereof:

• wherein:
• R1 is C1˜C4 normal or side chain alkyl, cycloalkyl, and C1-C4 alkylalkoxy or C1˜C4 alkylmercapto;
• R2 is H, halogen, C1˜C4 alkl, or arylalkyl;
• R3, R4 is same or different H, C1˜C4 normal or side chain alkyl, cycloalkyl, carbocyclic aryl, arylalkyl, arylcarbonyl, C1˜C4 alkoxycarbonyl, or aminocarbonyl, being optionally substituted by H, halogen, hydroxy, C1˜C4 alkoxy, amino, alkylamino or dialkylamino (each alkyl having C1˜C5), C1˜C4 alkoxycarbonyl or carboxy;
• R3 and R4 are together with N atom forming 4 to 8 membered heterocyclic ring, which can be further substituted with one or two substituents selected from the group consisting of cycloalkyl, carbocyclic aryl or arylalkyl, halogen, hydroxy, C1˜C4 alkoxy, amino alkylamino or dialkylamnino (each alkyl residue having C1˜C5), C1˜C4 alkoxycarbonyl, carboxy or aminocarbonly, and C1˜C4 normal or side chain alkyl being optionally substituted by H, wherein said heterocyclic ring can further include —O—, —S—, —SO—, —SO2— or >N—R5;
• R5 is H, C1C4 alkyl, carbocyclic aryl, arylalkyl, substituted alkenyl, pyridyl, pyrimidyl, C1˜C4 alkyl or arylcarbonyl, C1˜C4 alkyl or arylcarbonyl, C1˜C4 alkoxy carbonyl, aminocarbonyl, CN or SO2NR3R4;
• X is S or >N—R5;
• and
• Z is CN, COOR3, SO2NR3R4 or tetrazol-5-yl radical having the formula:
• wherein R6 is H, t-butyl or triplifenylmethyl;
• m is 1 or 2;
• and
• n is 1, 2, 3, 4, 5, and 6.